About Us
Products
Responsibility
Investors
Debt Seg
- Non convertible Debentures
Media
Careers
Worldwide
- North America
  - USA
  - Canada
  - Mexico
- South America
  - Brazil
  - Peru
- Asia Pacific
  - India
  - Bangladesh
  - Thailand
  - Malaysia
  - Singapore
  - Myanmar
  - Sri Lanka
  - Japan
  - China
- Europe
  - Denmark
  - Finland
  - France
  - Germany
  - Hungary
  - Italy
  - Norway
  - Poland
  - Romania
  - Spain
  - Sweden
  - Switzerland
  - The Netherlands
  - The United Kingdom & Ireland
- Middle East
  - UAE
- Africa
  - Morocco
  - Nigeria
  - South Africa
  - Egypt
  - Kenya
- Oceania
  - Australia & New Zealand
- CIS
  - Russia
  - Ukraine
Contact Us

Select Page

Non Convertible Debentures

Non Convertible Debentures

2026

Debenture Trustee Appointment Agreement (DTA)

Board Meeting Outcome for approval of NCDs

Board Meeting Intimation for issuance of NCDs

About Sun Pharma
- Vision & Values
- Milestones & Recognitions
Operations
Investors
Work with us
- Careers
- Current Openings
Quick Links

Facebook
X
Instagram
Linkdin
Instagram

Copyright © Sun Pharmaceutical Industries Ltd. Privacy Policy | Disclaimer

Top

Important Notice

As per SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 dated March 16, 2023 it is mandatory for all the shareholders holding shares in physical form to update their KYC and other details.